ORBIMED ADVISORS LLC 13D and 13G filings for Terns Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-09-16 8:29 pm Unchanged | 2024-09-12 | 13D | Terns Pharmaceuticals, Inc. TERN | ORBIMED ADVISORS LLC | 7,562,971 9.000% | 0 (Unchanged) | Filing |
| 2024-07-18 5:33 pm Sale | 2024-07-16 | 13D | Terns Pharmaceuticals, Inc. TERN | ORBIMED ADVISORS LLC | 7,562,971 11.700% | -56,164 (-0.74%) | Filing |
| 2023-03-29 5:24 pm Unchanged | 2023-03-27 | 13D | Terns Pharmaceuticals, Inc. TERN | ORBIMED ADVISORS LLC | 7,619,135 13.400% | 0 (Unchanged) | Filing |
| 2022-12-28 5:14 pm Purchase | 2022-12-23 | 13D | Terns Pharmaceuticals, Inc. TERN | ORBIMED ADVISORS LLC | 7,619,135 15.400% | 137,931 (+1.84%) | Filing |
| 2022-08-18 4:39 pm Purchase | 2022-08-16 | 13D | Terns Pharmaceuticals, Inc. TERN | ORBIMED ADVISORS LLC | 7,481,204 19.900% | 3,690,000 (+97.33%) | Filing |
| 2021-02-22 6:31 pm Purchase | 2021-02-09 | 13D | Terns Pharmaceuticals, Inc. TERN | ORBIMED ADVISORS LLC | 3,791,204 15.100% | 3,791,204 (New Position) | Filing |